Background/Aims: ARO, an observational study of hemodialysis (HD) patients in Europe, aims to enhance our understanding of patient characteristics and practice patterns to improve patient outcome. Methods: HD patients (n = 8,963) from 134 Fresenius Medical Care facilities treated between 2005 and 2006 were randomly selected from 9 European countries (Czech Republic, France, Hungary, Italy, Poland, Portugal, Spain, Slovak Republic and Slovenia) and Turkey. Information was captured on demographics, comorbidities, medications, laboratory and dialysis parameters, and outcome. Results: Patients were followed for 1.4 ± 0.7 years. Wide variation by country was observed for age, sex and diabetes as a cause of chronic kidney disease. Cardiovascular disease was present in 73% of patients. Dialysis parameters were homogeneous across countries. Arteriovenous fistulas were frequently used (73%). More incident patients had hemoglobin <11 g/dl than prevalent patients (50 vs. 33%, respectively). Phosphatemia and intact parathyroid hormone were similar between incident and prevalent patients (4.7 ± 1.2 mg/dl and 190 vs. 213 ng/l, respectively). Medication use varied widely by country. In total, 5% of patients underwent renal transplantation. Overall death rate was 124/1,000 patient-years. Conclusion: ARO revealed differences in HD practice patterns and patient characteristics in the 10 participating countries. Future ARO studies will fill gaps in the knowledge about the care of European HD patients.

Keywords:
Anemia, Epidemiology, Hemodialysis, Mineral disorders, Mortality, practice patterns
1.
Lameire N, Jager K, Van Biesen W, de Bacquer D, Vanholder R: Chronic kidney disease: a European perspective. Kidney Int Suppl 2005;99:S30–S38.
2.
Bommer J: Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17(suppl 11):8–12.
3.
Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United states: case-mix effects. Am J Kidney Dis 2004;44:16–21.
4.
Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2004;44:305–316.
5.
Port FK, Orzol SM, Held PJ, Wolfe RA: Trends in treatment and survival for hemodialysis patients in the United States. Am J Kidney Dis 1998;32:S34–S38.
6.
Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481–488.
7.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–2218.
8.
Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003;14:3270–3277.
9.
Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM: Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis 2009;53:79–90.
10.
Hecking E, Bragg-Gresham JL, Rayner HC, Pisoni RL, Andreucci VE, Combe C, Greenwood R, McCullough K, Feldman HI, Young EW, Held PJ, Port FK: Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:100–107.
11.
Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108–120.
12.
Locatelli F, Pisoni RL, Akizawa T, Cruz JM, Deoreo PB, Lameire NH, Held PJ: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004;44:27–33.
13.
den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW: The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006;21:1588–1595.
14.
Jager KJ, Merkus MP, Huisman RM, Boeschoten EW, Dekker FW, Korevaar JC, Tijssen JG, Krediet RT: Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001;12:1272–1279.
15.
Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT: Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000;35:69–79.
16.
Fernández MJL, Ferreira A, Floege J, Bradbury BD, Benedik M, Pavlovic D, Verbeelen D, Nagy J, MotellΔn JL, Carter D, Locatelli F, Cannata-And¡a JB, COSMOS Group: Results from the initial cross-sectional analysis of the COSMOS baseline population (abstract). Nephrol Dial Transplant 2006;21 (suppl 4):MP358.
17.
Marcelli D, Moscardo V, Steil H, Day M, Kirchgessner J, Mitteregger A, Orlandini G, Gatti E: Data management and quality assurance for dialysis network; in Ronco C, La Greca G (eds): Hemodialysis Technology. Contrib Nephrol. Basel, Karger, 2002, vol 137, pp 293–299.
18.
Marcelli D, Kirchgessner J, Amato C, Steil H, Mitteregger A, Moscardo V, Carioni C, Orlandini G, Gatti E: EuClid (European Clinical Database): a database comparing different realities. J Nephrol 2001;14(suppl 4):S94–S100.
19.
Steil H, Amato C, Carioni C, Kirchgessner J, Marcelli D, Mitteregger A, Moscardo V, Orlandini G, Gatti E: EuClid – a medical registry. Methods Inf Med 2004;43:83–88.
20.
Rothman KJ, Greenland S: Modern Epidemiology. Philadelphia, Lippincott-Raven, 1998.
21.
Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205–1213.
22.
Stel VS, Van Dijk PC, van Manen JG, Dekker FW, Ansell D, Conte F, Kramar R, Leivestad T, Vela E, Briggs JD, Jager KJ: Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant 2005;20:2803–2811.
23.
Pisoni RL: Vascular access use and outcomes: Results from the DOPPS; in Ronco C, La Greca G (eds): Hemodialysis Technology. Contrib Nephrol. Basel, Karger, 2002, vol 137, pp 13–19.
24.
Port FK, Wolfe RA, Hulbert-Shearon TE, McCullough KP, Ashby VB, Held PJ: High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 2004;43:1014–1023.
25.
Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW: Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007;2:89–99.
26.
Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858–1865.
27.
United States Renal Data System. 2004 Annual Data Reports: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004. http://www.usrds.org/atlas_2004.htm (accessed Feb 10, 2010).
28.
Levi F, Lucchini F, Negri E, La VC: Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002;88:119–124.
29.
Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ, Pisoni RL: Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2008;23:3219–3226.
30.
Lacson E Jr, Wang W, Lazarus JM, Hakim RM: Hemodialysis facility-based quality-of-care indicators and facility-specific patient outcomes. Am J Kidney Dis 2009;54:490–497.
31.
Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823–834.
32.
Couchoud C, Kooman J, Finne P, Leivestad T, Stojceva-Taneva O, Ponikvar JB, Collart F, Kramar R, de Francisco A, Jager KJ: From registry data collection to international comparisons: examples of haemodialysis duration and frequency. Nephrol Dial Transplant 2009;24:217–224.
33.
Andreucci VE, Fissell RB, Bragg-Gresham JL, Ethier J, Greenwood R, Pauly M, Wizemann V, Port FK: Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004;44:61–67.
34.
Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–248.
35.
Fellstrom B, Holdaas H, Jardine AG, Svensson MK, Gottlow M, Schmieder RE, Zannad F: Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25:271–285.
36.
Winkelmayer WC, Charytan DM, Levin R, Avorn J: Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 2006;47:301–308.
37.
Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC: Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010;21, in press.
38.
Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010 (E-pub ahead of print).
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.